Name | AS2444697 |
---|---|
Synonyms |
AS 2444697
N-[3-Carbamoyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methyl-4-pyridinyl)-1,3-oxazole-4-carboxamide hydrochloride (1:1) MFCD30182294 4-Oxazolecarboxamide, N-[3-(aminocarbonyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methyl-4-pyridinyl)-, hydrochloride (1:1) N-[3-Carbamoyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide AS2444697 N-[3-(Aminocarbonyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl-2-(2-methyl-4-pyridinyl)-4-Oxazolecarboxamide hydrochloride (1:1) |
Description | A potent, selective, orally bioavailable IRAK-4 inhibitor that potently inhibits human and rat IRAK-4 activity with subnanomolar order, >30-fold selectivity over IRAK-1; inhibited IL-1β- or TLR ligand lipopolysaccharide (LPS)-induced IL-6 production in human lung alveolar epithelial cells, fibroblast-like synoviocytes, and peripheral blood mononuclear cells; significantly reduces urinary protein excretion and preventd the development of glomerulosclerosis and interstitial fibrosis without affecting the blood pressure in mice model of chronic kidney disease. |
---|---|
References | References 1. Kondo M, et al. Naunyn Schmiedebergs Arch Pharmacol. 2014 Oct;387(10):909-19. 2. Imanishi J, et al. Arthritis Rheum 63:S390. View Related Products by Target IRAK |
Molecular Formula | C19H21ClN6O4 |
---|---|
Molecular Weight | 432.861 |
Exact Mass | 432.131287 |
Hazard Codes | Xi |
---|